News

EMA Reviews Teclistamab for Earlier Use in Relapsed Multiple Myeloma.

Drug Approvals /

Johnson & Johnson has submitted an application to the European Medicines Agency to expand the use of Teclistamab (Tecvayli) for patients with relapsed or refractory Multiple Myeloma. The request seeks to move the therapy from a fourth-line treatment to a second-line option, allowing patients to receive the immunotherapy earlier in their treatment course. The application […]

EMA Reviews Teclistamab for Earlier Use in Relapsed Multiple Myeloma. Read More »

Phase 2 Trial Highlights Promising Results for Relma-Cel in Mantle Cell Lymphoma

Immunotherapy /

A phase 2 clinical trial (NCT04718883) has shown promising results for relmacabtagene autoleucel (relma-cel), an anti-CD19 CAR T-cell therapy, in patients with relapsed or refractory mantle cell lymphoma who had already failed at least two previous treatments, including BTK inhibitors. The study included 59 heavily pretreated patients with a median age of 59. The therapy

Phase 2 Trial Highlights Promising Results for Relma-Cel in Mantle Cell Lymphoma Read More »

L1CAM Identified as Key Driver of Glioblastoma Spread, Offering New Treatment Target

Targeted Therapy /

A new study reveals that the protein L1CAM (CD171) plays a key role in driving the aggressive spread of Glioblastoma (GBM) cells into healthy brain tissue. Glioblastoma is notoriously difficult to treat because its cells migrate away from the main tumor, leading to relapse. Researchers used patient-derived neurosphere cells grown in serum-free conditions to better

L1CAM Identified as Key Driver of Glioblastoma Spread, Offering New Treatment Target Read More »

Targeting SLFN5 Could “Heat Up” Pancreatic Tumors and Boost Immunotherapy

Immunotherapy /

A new study identifies the protein SLFN5 as a key barrier to effective treatment in Pancreatic Ductal Adenocarcinoma (PDAC). SLFN5 acts as an “intracellular immune checkpoint,” helping tumors remain “cold” by evading immune attack and resisting standard therapies. High levels of SLFN5 are linked to poor patient survival. While Interferons normally activate anti-tumor defenses, SLFN5

Targeting SLFN5 Could “Heat Up” Pancreatic Tumors and Boost Immunotherapy Read More »

Silent TP53 Defects Drive High-Risk AML Despite “Normal” Genes

Research Advances /

A new study highlights how defects in the TP53-mediated apoptosis pathway affect survival in adult Acute Myelogenous Leukemia (AML), even when the TP53 gene appears normal. Mutations in TP53 are well-known markers of poor prognosis because they allow leukemia cells to resist chemotherapy and accumulate additional mutations. However, researchers found that a significant portion of

Silent TP53 Defects Drive High-Risk AML Despite “Normal” Genes Read More »

GnP vs. FOLFIRINOX in Pancreatic Cancer: Study Highlights Role of Genetic Markers

Precision Medicine /

A study compared two standard first-line chemotherapy regimens for advanced Pancreatic Ductal Adenocarcinoma (PDAC): FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP), examining how genetic markers, including BRCA2 and Tumor Mutational Burden (TMB), affect outcomes. In the overall population, GnP showed a slight survival advantage over FFX, supporting its use as a standard first-line therapy. Patients

GnP vs. FOLFIRINOX in Pancreatic Cancer: Study Highlights Role of Genetic Markers Read More »

ctDNA Testing Shows Promise for Early Detection in Metastatic Gastroesophageal Cancer

Diagnostics /

A recent observational study published in the journal Cancer highlights the expanding role of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in patients with metastatic gastroesophageal cancer. In an interview with Targeted Oncology, Dr. Rutika Mehta explained that although ctDNA is commonly used in early-stage cancers, it may also provide valuable insights for

ctDNA Testing Shows Promise for Early Detection in Metastatic Gastroesophageal Cancer Read More »

Continuing Zenocutuzumab After Progression Shows Benefit in NRG1-Positive NSCLC

Targeted Therapy /

A post hoc analysis of the Phase 2 eNRGy trial, presented at the 2026 TTLC Meeting, suggests that continuing Zenocutuzumab-zbco (Bizengri) after initial disease progression can provide meaningful benefits for patients with NRG1 fusion-positive non-small cell lung cancer (NSCLC). Standard practice often stops a therapy when imaging shows progression, but the study found that many

Continuing Zenocutuzumab After Progression Shows Benefit in NRG1-Positive NSCLC Read More »

Mezigdomide Combo Improves Outcomes in Relapsed Multiple Myeloma

Immunotherapy /

The phase 3 SUCCESSOR-2 trial has shown that adding Mezigdomide to a treatment combination of Carfilzomib and Dexamethasone significantly improves progression-free survival in patients with relapsed or refractory Multiple Myeloma. The study included patients who had received at least one previous line of therapy, including treatment with Lenalidomide and anti-CD38 antibodies, a group that often

Mezigdomide Combo Improves Outcomes in Relapsed Multiple Myeloma Read More »

ImmunityBio Resubmits Nogapendekin alfa inbakicept-pmln (Anktiva) Application to U.S. Food and Drug Administration for Papillary-Only Bladder Cancer

Immunotherapy /

ImmunityBio has resubmitted a supplemental biologics license application to the U.S. Food and Drug Administration seeking approval for Nogapendekin alfa inbakicept-pmln (Anktiva) to treat patients with BCG-unresponsive, non-muscle-invasive bladder cancer who have papillary-only tumors. The FDA had previously issued a refusal-to-file letter in May 2025, but after a January 2026 meeting the agency requested updated

ImmunityBio Resubmits Nogapendekin alfa inbakicept-pmln (Anktiva) Application to U.S. Food and Drug Administration for Papillary-Only Bladder Cancer Read More »